Lipe & Dalton’s Novo Nordisk NVO Stock Holding History

Lipe & Dalton’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-48,598	Closed	-$1.04M	–	87
2017 Q2	$1.04M	Hold	48,598	–	–	0.68%	41
2017 Q1	$833K	Hold	48,598	–	–	0.6%	38
2016 Q4	$871K	Sell	48,598 -800	-2%	-$14.5K	0.62%	38
2016 Q3	$1.03M	Hold	49,398	–	–	0.69%	40
2016 Q2	$1.33M	Buy	49,398 +36,398	+280%	+$998K	0.92%	37
2016 Q1	$352K	Hold	13,000	–	–	0.28%	47
2015 Q4	$378K	Hold	13,000	–	–	0.31%	45
2015 Q3	$353K	Hold	13,000	–	–	0.29%	49
2015 Q2	$356K	Sell	13,000 -2,000	-13%	-$56.2K	0.26%	49
2015 Q1	$400K	Hold	15,000	–	–	0.28%	46
2014 Q4	$317K	Hold	15,000	–	–	0.21%	52
2014 Q3	$357K	Hold	15,000	–	–	0.23%	47
2014 Q2	$346K	Hold	15,000	–	–	0.22%	47
2014 Q1	$322K	Hold	15,000	–	–	0.22%	46
2013 Q4	$277K	Hold	15,000	–	–	0.19%	50
2013 Q3	$254K	Hold	15,000	–	–	0.19%	51
2013 Q2	$232K	Buy	+15,000	New	+$250K	0.19%	46

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return

Lipe & Dalton's NVO Position: Q3 2017 in Review

Lipe & Dalton sold out of Novo Nordisk (NVO) in Q3 2017, closing a stake of 48,598 shares — an estimated $1.04M sold.

Lipe & Dalton first reported a position in NVO in Q2 2013 and held it in 17 quarters. The position peaked at $1.33M in Q2 2016. 491 funds tracked by Wall St. Rank hold NVO as of Q3 2017.

Lipe & Dalton reported no remaining Novo Nordisk position as of Q3 2017 after selling out during the quarter.
Lipe & Dalton sold 48,598 Novo Nordisk shares in Q3 2017, an estimated $1.04M.
Lipe & Dalton first reported a position in Novo Nordisk in Q2 2013 and held it in 17 quarters.
Lipe & Dalton's Novo Nordisk position peaked at $1.33M in Q2 2016.
491 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2017.

Based on Lipe & Dalton's 13F filing for Q3 2017, filed 3 Nov 2017.